Author:
Alzoman Nourah Z.,Darwish Ibrahim A.,Abuhejail Reem M.
Subject
Medical Laboratory Technology,Clinical Biochemistry,Immunology,Immunology and Allergy
Reference15 articles.
1. Chanan-Khan , A. A.Immunomodulating Drugs for the Treatment of Cancer,, 1st Ed. ; Lippincott Williams : Baltimore , MD , 2011 ; pp. 15 – 27 .
2. Hugin , R. J. Revlimid® in Combination with Dexamethasone sNDA Granted Approval by FDA for Treatment of Multiple Myeloma . Celgene Corporation: Summit, NJ, 2011. Available at http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=877894&highlight
3. Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
4. Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献